WO2004060387A1 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia - Google Patents
Compositions and methods for the prevention and control of insulin-induced hypoglycemia Download PDFInfo
- Publication number
- WO2004060387A1 WO2004060387A1 PCT/US2003/041103 US0341103W WO2004060387A1 WO 2004060387 A1 WO2004060387 A1 WO 2004060387A1 US 0341103 W US0341103 W US 0341103W WO 2004060387 A1 WO2004060387 A1 WO 2004060387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- glucagon
- administration
- administered
- hypoglycemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Definitions
- the present invention relates to the fields of biology, pharmacology, and medicine.
- Insulin is produced by the beta cells and glucagon by the alpha cells of the Pancreatic Islets of Langerhans.
- One of insulin's major effects is to lower blood glucose by suppressing hepatic glucose output and stimulating peripheral glucose uptake. Endogenous insulin levels may be low or undetectable in some patients with diabetes mellitus. Exogenous insulin is usually administered to reduce hyperglycemia in situations where circulating insulin levels are either low or ineffective.
- Glucagon generally has effects opposite to those of insulin, including, primarily, increasing hepatic glucose output and thereby increasing blood sugar levels. Glucagon levels tend to increase when blood glucose levels fall to abnormally low levels, particularly in patients who utilize exogenous insulin.
- hypoglycemia and the conditions that can result from a lack of awareness of its presence are serious complications of chronic insulin therapy and can occur due to the impaired counter-regulatory (anti-insulin) responses in diabetic patients.
- anti-insulin anti-insulin
- One of the major counter-regulatory hormones that normally responds to hypoglycemia is glucagon.
- the glucagon response to acute hypoglycemia is impaired or lost in patients with advanced Type 1 and Type 2 diabetes.
- the present invention provides pharmaceutical compositions comprising both insulin and glucagon in amounts that can be administered to a diabetic patient not only to achieve therapeutically effective control of diabetes but also to prevent hypoglycemia.
- the formulations of the invention include formulations suitable for injection, formulations suitable for administration orally, formulations suitable for transdermal administration, formulations suitable for ocular administration, and formulations suitable for inhalation.
- the present invention provides methods to treat diabetes in a human or other mammal without inducing hypoglycemia, which comprise co-administration of insulin and glucagon, wherein said insulin is administered in amounts therapeutically effective for the control of diabetes, and said glucagon is administered in amounts therapeutically effective for the prevention of hypoglycemia, and wherein both insulin and glucagon are administered simultaneously with one another or within about less than four hours of each other (as when regular, LISPRO, and ASP ART insulins are used) or within less than about six to twelve hours of each other .(as when longer acting insulins are used), and in any event prior to the onset of clinically observable hypoglycemia.
- the present invention provides a method to maintain blood glucose levels in a range that is neither hyperglycemic nor hypoglycemic which comprise co-administration of insulin and glucagon.
- the present invention provides glucagon formulations and modified glucagon suitable for co-administration with insulin in accordance with the methods ofthe present invention.
- Figure 1 is a graph illustrating idealized pharmacokinetics for a mixture of regular and intermediate acting insulin.
- the graph shows the effect of a twice-daily insulin regimen: Twice-daily administration of regular (solid lines) and intermediate- acting LENT or NPH (dashed lines) insulins before breakfast and the evening meal provides peaks of insulin after the injections as well as a relatively constant baseline level of insulin throughout the day after injections ofthe intermediate-acting insulins.
- Figure 2 is a graph illustrating the insulin profile of a hypothetical patient, as described in Example 1, Part A(i), showing a very simple, flat line graph (basal level set by the GLARGINE (LANTUS)) punctuated by peaks corresponding to prandial LISPRO (HUMALOG) insulin injections.
- GLARGINE LANTUS
- Figure 3 is a schematic of a drug delivery pump configured for practice ofthe present invention.
- Figure 4 is a schematic of a drug delivery pump configured for practice ofthe present invention.
- Figure 5 is a schematic of a drug delivery pump configured for practice ofthe present invention.
- Figure 6 illustrates the effect of molecular weight and lipophlicity on the rate of transdermal transport in case of permeation (upper and lower grey curve for the more or less lipophilic substances, respectively) or of the TRANSFEROME® mediated penetration (black line and bullets). Dotted black bullets represent the commercial drugs in transdermal patches.
- Figure 7 is a graph illustrating the insulin and glucagon profiles of a hypothetical patient, as described in Example 6, showing for both drugs a very simple, flat line graph (basal insulin and glucagon infusions) punctuated by peaks (corresponding to prandial insulin and glucagon infusions) that would pertain when glucagon and insulin are administered in an admixed formulation.
- the present invention provides methods and compositions that can prevent, or significantly reduce the frequency and severity of, hypoglycemia in insulin-treated diabetic patients (both Type 1 and 2).
- the methods and compositions ofthe invention can be used to replenish or restore the abnormally low glucagon responses often coincident with insulin administration, thereby preventing hypoglycemia.
- the invention in one aspect, provides pharmaceutical formulations of two hormones, insulin and glucagon, combined in molar ratios that optimize glycemic management and attenuate the incidence of or prevent hypoglycemia.
- the invention provides methods and compositions for the simultaneous but separate administration of insulin and glucagon to achieve this benefit.
- the present invention provides a method for controlling diabetes with a reduced risk of hypoglycemia by simultaneous administration of insulin and glucagon to a diabetic patient.
- the invention provides a method of preventing hypoglycemia in a diabetic patient who is being treated with insulin and who is not suffering hypoglycemic symptoms, by administering glucagon to the patient in an amount therapeutically effective for the prevention of hypoglycemia.
- the glucagon is administered simultaneously with, or within one minute to four hours after said patient has last been administered insulin.
- any of the many different forms of insulin as well as any ofthe many different routes of administration of insulin, including those both approved by the FDA and in development, can be used in the methods and formulations of the invention.
- any ofthe currently available formulations of glucagon can similarly be used in the methods and formulations of the invention.
- the present invention provides new glucagon derivatives and new formulations of and methods of administering glucagon that are particularly suited to achieve the benefits provided by the present invention, including delayed and/or extended action glucagon.
- the beneficial effects ofthe invention can generally be achieved by administering both insulin and glucagon in the ratio of 1 unit of Insulin to 0.02 - 40 milliunits of glucagon (0.02 to 40 micrograms). In a preferred embodiment, the ratio is 1 unit of insulin to 0.2 to 4.0 milliunits of glucagon (0.2 to 4.0 micrograms).
- the benefits of the present invention can be achieved by administration of any ofthe currently available forms of insulin, including but not limited to recombinant human soluble (regular) insulin, human insulin analogs, animal insulins, derived, for example, from beef, pork and other species, as well as delayed release forms, including intermediate and long acting insulin.
- any ofthe currently used routes of administration, as well as newer routes in development can be employed, including but not limited to subcutaneous, intramuscular, and intravenous injection, as well as oral, buccal, nasal, transdermal, and pulmonary airway administration. Typical doses and dose ranges for the administration of insulin to control diabetes known in the art are suitable for use in the methods and compositions ofthe invention.
- prandial short-acting insulins such as regular insulin and the LISPRO and ASP ART derivatives thereof, are well known in the art and commonly used to treat diabetes.
- Such insulins can be used to illustrate the invention in a manner applicable to other forms, including but not limited to NPH, LENTE, SEMI-LENTE, DETEMIR, ULTRA-LENTE, and GLARGINE (LANTUS), and pre-mixed formulations of regular and long-acting insulins.
- the molecular weights ascribed to all three of these prandial short-acting insulins are similar, with LISPRO at 5808, ASP ART at 5825.8 and regular insulin at 5807, and the molecular weight ascribed to glucagon is 3483.
- the usual range of prandial insulin injections in Type 1 diabetes can be approximated as two standard deviations from the mean, resulting in an insulin dose range of 2 - 20 units. More than 95% of Type 1 diabetics will be administered a prandial insulin dose within this range.
- the three prandial insulins noted above all achieve peak serum concentrations within 1-2 hours after subcutaneous administration and have a duration of about 5 hours.
- hypoglycemia is treated by a single parenteral injection of glucagon in a dose of about 1 mg (1 unit); this dose is a gross excess ofthe dose actually required to control hypoglycemia.
- glucagon is given subcutaneously or intramuscularly, serum glucagon peaks within an hour, and its effects can persist for several hours.
- the present invention provides longer-acting glucagon formulations and derivatives that can be used to correct this mis-match, where desired or of benefit to the patient.
- "Longer-acting" glucagon has a half-life greater than that of standard glucagon (natural extract or rDNA produced synthetic glucagon).
- the usual basal glucagon replacement dose by IV infusion is 0.5- 0.75 ng/kg/min; one can assume that a wider range of glucagon infusions, from as low as 0.10 to 5.00 ng/kg/min (more often, 0.10 to 3.00 ng/kg/min) can be effective, depending on the patient, the insulin dose, and other factors.
- these glucagon infusion rates would be administered for a period of time ranging from 150 minutes to 300 minutes. One can then multiply the replacement rates by the minimum and maximum times to give the total dose/kg.
- the insulin/glucagon ratios can be calculated as shown in the Table below.
- Insulin/Glucagon Weight Ratios (ng/ng) and Inverse Ratio [% terms]
- Glue Means that a TOTAL of 2 Units of Insulin are administered over the given infusion period, and that Glucagon is administered over the period of infusion at a rate of O.lng/kg/min.
- the glucagon is present at 0.09 - 188% of the weight of insulin (or 0.09 - 112.3% when 2 U Insulin/ 3.0 ng/kg/min Glucagon is the upper infusion duration); for most patients, however, the glucagon will most often be administered at, or be present in a composition of the invention at ⁇ 5% the weight of insulin (given that typical basal Glucagon basal replacement rates are between 0.50-0.75 ng/kg/min).
- compositions for use according to the invention include all of those compositions useful in conventional methods for the control of diabetes and hypoglycemia.
- Such conventional methods include those approved by the FDA, those in development, and those described in Diagnosis and Management of Type II Diabetes, by SN. Edelman and R.R. Henry (5 th Ed. PCI Publishers), the entire text of which is incorporated herein by reference, and Chapters 7 and 8 of which are especially pertinent.
- a pharmaceutical formulation or pharmaceutical composition may contain a pharmaceutically acceptable excipient, diluent or carrier.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- Pharmaceutically acceptable excipients are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy (19th edition, 1995, Gennavo, ed.).
- Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.
- the methods of the present invention can be practiced using such methodology, although, as noted above, it may be preferable in some instances to provide glucagon in a manner that ensures that its duration of action more closely matches that ofthe insulin employed such that the glucagon is present when the risk of hypoglycemia is greatest - typically a relatively long time after eating but still within the period in which the insulin administered continues to exert its effect.
- the present invention provides a variety of methods to achieve the benefits of diabetes control and prevention of hypoglycemia.
- a glucagon with a shorter duration of action than the insulin is administered within about one to four hours after the insulin is administered.
- This method provides benefit in that most hypoglycemic episodes begin several hours after the patient has last eaten, and many patients administer insulin shortly before a meal.
- delivering the glucagon a few hours after the insulin, but in any event prior to the onset of hypoglycemic symptoms, one can achieve the benefit of the invention.
- the insulin and glucagon can be administered simultaneously, with the insulin and optionally the glucagon delivered parenterally, including by subcutaneous injection, but in this method, a glucagon with a longer duration of action is employed, or the glucagon is administered by a route that provides a longer duration of action.
- glucagon includes, but is not limited to, the glucagon, glucagon formulations, and routes of administration described in U.S. patent application publication No. 2002114829 and U.S. Patent Nos. 6,197,333 and 6,348,214, which describe liposome formulations of glucagon that provide for reduced dosage effect and are long acting; PCT patent publication No.
- WO0243566 which describes the delivery of glucagon via trans-dermal patch
- U.S. Patent No. 5,445,832 which describes a long-acting glucagon formulation in polymeric microspheres
- PCT patent publication No. WO0222154 which describes a slow-release glucagon that can have a duration of action measured in weeks
- U.S. Patent No. 3,897,551 and Great Britain Patent No. 1,363,954 which describes the prolongation of glucagon duration by iodination.
- the glucagon is administered as a slow-release or depot formulation (e.g., comprising polyethylene glycol).
- parenteral administration can be performed by means of an infusion pump.
- a variety of insulin pumps are available and in common use that are suitable for delivery ofthe insulin and glucagon compositions ofthe invention (as well as suitable for the delivery of insulin, with glucagon being delivered by another route, such as transdermal or subcutaneous administration).
- Such pumps include, for example and without limitation, the pumps marketed by Medtronic (the MiniMed), Animas Corporation, Disetronic, and Dana.
- the glucagon can optionally be administered with the insulin, and a glucagon with a short duration of action can be employed, as the glucagon can be administered as necessary.
- the glucagon can be administered at a rate of 0.5-0.75 ng/kg/min or within the wider range of 0.10 - 5 ng/kg/min (alternatively, within the range 0.10 - 3 ng/kg/min).
- the present invention provides a pump suitable for the delivery of insulin, for the control of diabetes, and glucagon for the control of hypoglycemia in a human, which pump contains both insulin and glucagon.
- the pump includes a reservoir containing both insulin and glucagon.
- the pump includes insulin and glucagon in two separately controlled reservoirs.
- the invention provides a method of controlling diabetes in a human patient with a reduced risk of hypoglycemia, said method comprising administering both insulin and glucagon to the diabetic patient using a pump of the invention.
- either the insulin or the glucagon or both is provided in a formulation that is a powder or a liquid suitable for administration as a nasal or pulmonary spray or for ocular administration.
- a formulation that is a powder or a liquid suitable for administration as a nasal or pulmonary spray or for ocular administration.
- a variety of such formulations are known for either insulin or glucagon, and the present invention provides methods for using these known formulations, as well as the corresponding formulations of the invention that comprise both insulin and glucagon to control diabetes with a reduced risk of inducing hypoglycemia.
- Such known formulations and methods of administration useful in the methods of the invention include those in PCT patent publication Nos. WOO 182874 and WOO 182981, which describe aerosolized insulin and glucagon; European patent publication EP1224929 and U.S. Patent No. 6,004,574, which describe an inhaled glucagon with melezitose diluent; U.S. Patent No. 5,942,242, which describes formulations of insulin and formulations of glucagon suitable for nasal administration; U.S. Patent No. 5,661,130, which describes formulations suitable for ocular, nasal and nasolacrimal or inhalation routes of administration; U.S. Patent No.
- the invention also provides methods for controlling diabetes with a reduced risk of inducing hypoglycemia by administering insulin and glucagon, in which one or both of the insulin and glucagon is administered transdermally, e.g. from a patch, optionally a iontophoretic patch, or transmucosally, e.g. bucally.
- transdermal delivery devices are well known in the art (see, e.g., US Pat. Nos. 4,943,435 and 4,839,174; and patent publication no. US 2001033858).
- the transdermal delivery of glucagon, and a patent publication describing transdermal formulations of glucagon has been discussed above, and U.S. Patent No. 5,707,641 describes methods and formulations for the transdermal delivery of insulin.
- the methods of the invention can be practiced by oral administration of both insulin and glucagon in the therapeutically effective amounts described herein.
- Methods and formulations for the oral administration of insulin and of glucagon include those described in PCT patent publication No. WO9703688.
- the insulin and/or glucagon employed in the methods and formulations ofthe invention can be supplemented with or replaced by compounds and compositions that have similar activities or effects.
- glucagon may be replaced with glucagon mimetics.
- Insulin can be replaced or supplemented with insulin secretagogues including, but not limited to, sulfonylureas such as Acetohexamide (DYMELOR), Chlorpropamide (DIABINESE), Tolazamide (TOLINASE), Tolbutamide (ORINASE), Glimepiride (AMARYL), Glipizide (GLUCOTROL), Glipizide Extended Release (GLUCOTROL XL), Glyburide (DIABETA, MICRONASE), Glyburide Micronized (GLYNASE, PRESTAB); Meglitinides such as Nateglinide (STARLIX) and Repaglinide (PRANDIN); Gastric Inhibitory Polypeptide (GIP) [Stimulates GLP-1 ouput]; Glucagon-like peptide (GLP)-l; Mo hilinoguanide BTS 67582; Phosphodiesterase inhibitors; and succinate ester derivatives; insulin receptor activators; insulin sensitizing Biguanides such
- the only pharmaceutically active components of the formulation of the invention are insulin and glucagon.
- the pharmaceutical composition e.g., containing both insulin and glucagon
- the pharmaceutical composition is not formulated as an aerosol and/or does not contain troglitazone hydrochloride (and may not contain any thiazolidinedione).
- the formulation is not administered orally and/or is not administered nasally.
- the methods and compositions of the invention may be used to treat human patients as well as other mammals (e.g., rats, mice, pigs, non-human primates, and others).
- the human patient is a child or juvenile; in one embodiment the human patient is an adult.
- the patient is a type I diabetic.
- the patient is a type II diabetic.
- the patient is a brittle type I or type II diabetic.
- the non-human mammal is a animal models for the study of diabetes, e.g., Zucker diabetic-fatty (ZDF) rats, and db/db mice.
- ZDF Zucker diabetic-fatty
- glucagon Diagnostic Kit Lilly
- Glucagon Emergency Kit Lilly
- Glucagon Emergency Kit for Low Blood Sugar (Lilly)
- GLUCAGEN Bedford Labs
- the Lilly glucagon is typically provided in kit form.
- the glucagon within the kit is in the form of a powder within a sterile vial with a standard rubber-sealed neck.
- the vial contains a mixture of 1 mg of lyophilized glucagon, 49 mg lactose, and hydrochloric acid to adjust the pH (glucagon is soluble below pH 3 or above pH 9.5).
- the patient injects 1 ml of diluent from a pre-fiUed syringe (which contains 12 mg/ml of glycerine in a mixture of water, and hydrochloric acid) into the vial.
- the vial is shaken until the solution is clear.
- the liquid is returned to the syringe, and the entire dose is injected (children are typically administered 50% ofthe standard dose.).
- Glucagon is administered parenterally by subcutaneous, intramuscular, and intravenous routes, with the pharmacokinetic properties differing accordingly as understood by those of skill in the art.
- Maximum plasma concentration is achieved approximately 20 minutes after subcutaneous administration. The half life in vivo ranges from 8 to 18 minutes. Peak plasma concentration of approximately 8 ng/ml are achieved after approximately 20 minutes, and elevated glucose levels persist for approximately 1 l A hours after administration and begin rising almost immediately following administration. Patients with insulin-induced coma will typically recover consciousness within 15 minutes of glucagon administration.
- Parenteral glucagon when given to treat hypoglycemia, does so primarily by increasing serum glucose availability through increased output of glucose by the liver (the conversion of glycogen to glucose and formation of new glucose by gluconeogenesis).
- insulin dosage regimes There are a wide variety of insulin dosage regimes in use. The regime used depends on whether type-1 or type-2 diabetes is being treated and on a large number of factors specific to the individual being treated. It is normal medical practice to replace insulin using a combination of parenterally administered insulins (usually subcutaneously) of rapid onset/short acting duration (LISPRO (HUMALOG) or ASP ART (NOVOLOG)), slower onset/short acting duration (regular human insulin), intermediate duration (NPH or LENTE), long acting duration (ULTRALENTE) and 24 hour peak-less duration (GLARGINE (LANTUS) and DETEMIR). [0047] The dosage regimes can be quite complex.
- a typical twice-daily regimen might involve administering short acting and intermediate duration insulin before breakfast and supper.
- the insulin profile thus obtained has a number of peaks, which roughly correspond to the anticipated post-prandial glucose output, as well as providing a basal insulin level throughout any 24 hour period.
- Figure 1 [taken from h1tp://www.uptodate.com/patient_info/topicpages/pictures/ins_time.gifI, which shows the idealized pharmacokinetics for a mixture of regular and intermediate acting insulin.
- Insulin levels can vary significantly between individuals and even within the same individual, depending on factors such as site and depth of injection, local blood flow, total volume and type of insulin injection, and other factors appreciated by those of skill in the art.
- there can be significant inter and intra-patient variability in subcutaneous absorption of insulin which increases the likelihood of variations in serum glucose, including the possibility of hypoglycemia.
- GLARGINE Longerg., LANTUS
- DETEMIR is a long acting insulin in development
- ULTRALENTE is a long acting insulin but tends to have some peak effect in most patients
- the basic methodology is to replace basal insulin and prandial insulin through the combined use of insulin preparations having different rates of onset and durations of action. This may involve the use of separately administered insulins of differing onset, (e.g. GLARGINE and LISPRO) or the use of various pre-mixed formulations, (e.g. 70/30 - 70% NPH and 30% regular combined), which are commercially available for this purpose.
- the point at which the glucagon is administered in accordance with the methods of the invention is before, during, or immediately prior to the period when insulin action is most unopposed, for example when significant insulin action persists in the absence of sufficient serum glucose availability.
- insulin-induced hypoglycemia may occur whenever there is a mismatch between circulating insulin and glucose levels (a relative excess of insulin effect to glucose availability).
- the patient (all patients referred to herein are fictitious; any resemblance to an actual person is coincidental) is an adult male, 50 years of age, weighing 75 kg, with 5 L of blood, suffering from type-2 diabetes and using insulin therapy (without concomitant oral combination therapy). He has been using insulin for over 10 years and his glucagon response to hypoglycemia is minimal. His insulin regimen involves basal insulin replacement using GLARGINE (LANTUS) subcutaneous injections at a dosage level of 20 units administered at bedtime in addition to prandial insulin injections of LISPRO (HUMALOG) of between 5 and 10 units (depending on the amount of carbohydrate consumed) administered at mealtimes.
- GLARGINE LANTUS
- his insulin profile is very simple, being a flat line (basal level set by the GLARGINE (LANTUS)) punctuated by peaks corresponding to the prandial LISPRO (HUMALOG) insulin injections.
- This insulin profile is shown in Figure 2.
- the risk of hypoglycemia typically arises between 2 and 5 hours after the meal. It is during this period that administering glucagon is most efficacious and effective in preventing the possibility of a hypoglycemic episode.
- glucagon In non-diabetics, glucagon usually falls following a carbohydrate meal (in response to increased glucose levels) and then recovers subsequently as glucose levels return to normal.
- type-1 diabetics and type-2 diabetics of 5 years or more
- the glucagon response to low serum glucose is limited. Hence, if insulin causes the serum glucose level to drop well below the basal level, hypoglycemia will ensue.
- hypoglycemic symptoms are typically observed in diabetics at glucose levels less than 50 mg/dl, or sometimes less than 40 mg/dl.
- glucagon release would be augmented (by about 40 pg/ml or higher, e.g. about 60 pg/ml or higher) before glucose levels fell this low and would prevent the onset of hypoglycemic symptoms.
- glucagon production to hypoglycemic is deficient in most 0.10 to insulin-treated diabetics.
- administering glucagon to achieve these levels during the period of susceptibility will prevent or attenuate the severity of hypoglycemic attack.
- a unit of glucagon administered to a patient will produce a peak concentration of approximately 8 ng/ml (see Lilly's "Information for Physicians" sheet).
- the dose required to provide prophylaxis can be estimated to be about 1 /200th of a unit (lasting from between 1 and 3 hours in its effect).
- This dose corresponds to between 1.25% and 2.50% by weight ofthe insulin used (5-10 IU of insulin).
- this patient is administered l/200th of a unit of glucagon (using Eli Lilly's Glucagon Emergency Kit as described above administered subcutaneously) two hours after the meal. Two similar doses are administered hourly for an additional two hours.
- This dosage level (summing over the three doses of glucagon) corresponds to between 3.75% and 7.50% by weight of the prandial insulin administered (5-10 IU insulin).
- the lower percentage of glucagon (3.75%), as the risk and degree of hypoglycemia is (in part) insulin-dose-dependent.
- the glucagon concentration from the dose administered 2 hours after the meal will have fallen back to approximately basal levels after an hour, the elevation of blood sugar due to this dose will persist for more than one hour, giving time for the second dose to take effect.
- the same pharmacokinetics applies to the third dose of glucagon.
- two doses or even one dose of glucagon can be administered.
- this example employs a simple basal and prandial insulin model, it will be understood by those skilled in the art to be applicable to all currently practiced dosage regimens.
- the timing (and frequency) ofthe glucagon injections may be adjusted to match the period in which the patient is most susceptible to hypoglycemia, i.e. the point at which insulin action and glucose availability are most mismatched.
- a typical diabetic patient is an adult male, 63 years of age, weighing 75 kg, suffering from type-2 diabetes for 18 years and using combination insulin therapy (without concomitant oral anti-diabetic therapy).
- oral anti-diabetic medications including Glyburide and Glipizide, but these will have been stopped and insulin started when his serum glucose levels were consistently above 250 mg dl.
- He will have been using insulin of one type or another for over 10 years and will have developed evidence of background retinopathy, mild renal impairment with a serum creatinine of 1.9 mg/dl and creatinine clearance of 60 ml/min, mild proteinuria, bilateral distal symmetrical neuropathy in both feet, and exertional angina.
- His insulin regimen would typically involve a split-mixed regimen of subcutaneous NPH insulin, 20 units before breakfast and 15 units before dinner, which is intended to provide day-long basal insulin coverage plus modest postprandial coverage for lunch and the evening meal (and bedtime snack).
- regular insulin of between 6 and 10 units (depending on the level of pre-meal serum glucose as well as the size and carbohydrate content ofthe meal) before these meals.
- His insulin profile is similar to that shown in Figure 1, with less rapid peaks and slower decays resulting from the prandial injections of regular insulin and slower onset and delayed decay effects from the twice daily intermediate acting NPH insulin.
- His fasting glucose levels are typically well controlled in the range of 90-130 mg/dl, but his 1-2 hour postprandial glucose levels are suboptimal and generally range from 180 240 mg/dl.
- Glycosylated hemoglobin is elevated at 7.9% (normal range 4-6%).
- Efforts to increase his breakfast or evening meal dose of prandial regular insulin to reduce postprandial glucose levels is usually accompanied by frequent intermittent hypoglycemia, of mild to moderate severity, often 1-2 hours before lunch or dinner.
- hypoglycemia can be quite severe and associated with symptoms of sweating, tremors, nausea, and headaches, particularly when he is late for meals. He has never had insulin-induced hypoglycemic coma but is reluctant to increase his insulin dosage in case this happens. He fears that he could lose his driver's license if this occurs or perhaps his job as a night watchman. Because of this patient's long history of diabetes and presence of significant complications, it is expected that he will exhibit impaired glucose counter-regulation to hypoglycemia, especially manifest as a blunted or absent glucagon response.
- hypoglycemia In this patient, the risk of hypoglycemia is usually greatest between 3 and 5 hours after a meal (late postprandial hypoglycemia), when circulating insulin levels are still increased above fasting level but glucose availability (from gastrointestinal absorption and liver production) is minimal. It is during this period, prior to the onset of hypoglycemia, that the administration of glucagon would be most efficacious and effective in preventing the possibility of hypoglycemic episodes by increasing circulating glucose availability. In non-diabetic individuals, both insulin and glucagon are tightly regulated following a meal to balance glucose production and utilization so as to maintain normoglycemia. Should insulin effects become pronounced, glucagon levels will rise to offset this hypoglycemic potential.
- this patient is administered l/50th of a unit (20 ⁇ g) of glucagon given subcutaneously (optionally using Eli Lilly's Glucagon Emergency Kit, as described above) two to three hours after each meal.
- the glucagon is added when glucose measurements indicate glucose levels are approaching hypoglycemic levels.
- This administration provides the required protection between hours 3 and 5, as described above. Because one unit of glucagon (1 mg) will produce a peak concentration of approximately 8 ng/ml, l/50th of a unit will produce a peak concentration of approximately 160 pg/ml, which is intended to approximate normal basal levels and ensure that unopposed insulin action does not occur. This dosage level corresponds to less than 3% by weight ofthe prandial insulin administered.
- this illustrative example employs a simple basal and prandial insulin model, it will be understood by those skilled in the art to be applicable to virtually all currently practiced insulin dosage regimens.
- the glucagon injections are optimally timed and vary depending on the insulin regimen used but are designed to achieve sustained glucagon levels during the expected periods of relatively unopposed insulin action.
- this situation tends to occur at several times throughout the day. For example, hypoglycemia is prone to occur when the "tail" of injected regular insulin absorption combines with peaking insulin availability from the intermediate acting NPH. This situation occurs several hours after breakfast when serum glucose availability (primarily from gut absorption and liver production) is minimal or decreasing.
- the timing of glucagon injection in accordance with the methods of the invention can vary depending upon the pharmacologic characteristics and timing ofthe insulin(s) used.
- the dose of insulin acting during that hypoglycemic period can be increased somewhat to maintain euglycemia.
- the increased availability of glucagon provides a buffering action or cushion to the excessive glucose lowering action of insulin in those specific circumstances as described above and blunts or prevents hypoglycemia.
- Example 2 describes the administration of insulin by pump.
- the patient's insulin pump is programmed to provide a continuous stream of rapid-onset insulin (e.g. LISPRO or ASPART).
- ASPART rapid-onset insulin
- ASPART in doses of between 5 and 10 units at mealtimes according to the pre-meal glucose level and the amount of carbohydrate and calories consumed.
- the patient will then in accordance with the methods ofthe invention administer 1 /200th of a unit of glucagon (using Bedford Lab's GLUCAGEN product, for example) two hours after the meal and repeat the dose hourly for another two hours.
- the glucagon is administered subcutaneously. This administration provides protection from hypoglycemia between hours 2 and 5, as described in Example l.A.i.
- C. Insulin Administered Transdermally [Including Patch and Topical Cream]
- the patient is a 62 year old lean type-2 diabetic of 6 years duration. He was initially treated with Glyburide 20 mg twice daily and subsequently with the addition of Metformin 1 gram twice daily, but fasting and postprandial blood sugars were consistently in the range of 200-350 mg/dl. He is advised by his physician that insulin is required. The oral anti-diabetic medications are discontinued and GLARGINE (LANTUS) insulin 15 units is administered at bedtime to provide his daylong basal insulin replacement needs.
- GLARGINE LANTUS
- Postprandial insulin is administered by transdermal patch to provide 2-6 units of rapidly acting insulin (patches available in 2 unit increments; although this example refers to use of a patch, those of skill in the art will appreciate that substantially similar methodology is employed to practice the invention with insulin or glucagon delivered transdermally by other means, such as creams or lotions).
- he is offered the 24-hour basal insulin replacement patch instead of once daily GLARGINE.
- the basal insulin replacement patch contains insulin in a unique formulation designed to provide steady continuous absorption and low constant serum insulin levels throughout the day. Because of persistent elevation of fasting plasma glucose, his physician progressively increases his dose of GLARGINE insulin over 6 months to 24 units and transdermal patches to 4-10 units.
- fasting glucose levels ranged from 70-110 mg/dl and 1-2 hour postprandial glucose levels from 130-180 mg dl within 3 months.
- the patient applies the rapidly-acting insulin patches 30-60 minutes prior to meals. This timing is chosen so that absorption of the meal coincides with insulin patch absorption kinetics and action.
- This patient has near normal glycemic control as indicated above but begins to suffer from early morning hypoglycemia, typically at 1 or 2 a.m. At these times, this hypothetical patient is frequently confused, irritable, and at times anxious.
- Several readings of fingerstick glucose taken during these events reveal blood glucose values of 35-40 mg/dl with prompt resolution of symptoms with ingestion of juice.
- GLARGINE insulin back to 24 units at bedtime and prescribes administration of subcutaneous glucagon l/200th of a unit (using Bedford Labs Glucagon product) immediately following the injection of GLARGINE at -23:00.
- the time of administration of glucagon depends primarily on the rate of absorption, which is rapid, reaching peak levels within 15-30 minutes, and a duration of action of approximately 2 - 3 hours.
- the aim is to provide a level of plasma glucagon approximating normal basal levels during this period and prevent an unopposed action of insulin from GLARGINE insulin or a delayed action ofthe early evening (pre-dinner) patch.
- This therapy provides the required protection from hypoglycemia for approximately 3 hours after the GLARGINE injection, as described above.
- the early morning hypoglycemic episodes should resolve and day-long near-normal glycemia be preserved.
- D. Insulin by Inhalation including Pulmonary, Buccal, Nasal and Sublinguall [0067]
- This example is similar to Example LA.i, except the patient administers insulin by inhalation rather than by subcutaneous injection.
- Example 4 describes the administration of insulin by inhalation. It will be understood by those skilled in the art that similar methods apply when insulin is administered buccaly, nasally, or sublingually in accordance with the methods ofthe present invention. The patient will either continue to administer his basal need via GLARGINE (LANTUS) or he will utilize an insulin inhaler to administer basal insulin needs.
- GLARGINE LANTUS
- the patient will administer his prandial insulin need (equivalent to between 5 and 10 units administered by subcutaneous administration) using his insulin inhaler (either pulmonary, nasally, buccaly or sublingually).
- his insulin inhaler either pulmonary, nasally, buccaly or sublingually.
- the patient will then administer 1 /200th of a unit of glucagon (optionally using Lilly's Glucagon kit) two hours after the meal and another two doses hourly thereafter. He will administer the glucagon subcutaneously. This will provide the required protection from hypoglycemia between hours 2 and 5, as described in Example l.A.i.
- Insulin can be administered by pump in accordance with the methods of the present invention.
- pumps commercially available (or soon to be available) in the US market and elsewhere that are suitable for use in the present methods. These include but are not limited to:
- a single device with a single pump and two reservoirs for dual reservoir pumps, see, for example, U.S. Patent No. 5,474,552) with each drug delivered through 2 separate lines that are merged prior to cannulization;
- implantable pumps may be used to practice the invention in almost exactly the same way as is achieved using external pumps.
- Embodiment (1) above minimizes trauma to the patient on cannulization, reduces cost, simplifies infusions, and minimizes complexity.
- the single pump can be programmed to deliver appropriate volumes from each reservoir, each containing different concentrations of one of the two hormones. Such a pump is provided by the present invention.
- the internal pump mechanism usually comprises an electromagnetically driven pulsatile pump having a solenoid operated piston mounted for reciprocation within a cylinder to draw medication from an internal storage chamber
- delivery lines used with pump insulin are typically one-half to one meter in length with lumen diameters ofthe order of 1/lOth of a millimeter (dead volume ofthe order of a l/10th of a milliliter or about 10 IU of Insulin), the time delay between a new drug reaching the body and the time at which the pump starts infusing it is likely to be substantial (about half a day).
- the present invention provides pumps with lines of much shorter length and/or of very small internal lumen diameter that enable the lag time between a switch in drugs to be much shorter.
- the present invention also provides peristaltic type pumps acting on two delivery lines.
- the present invention also provides a system comprising a pump and a set of four valves, two immediately before and two immediately after the pump, which when operated in pairs, control which drug is pumped.
- the two lines are, in one embodiment, merged at the point of cannulization, thereby eliminating the lag or (dead volume) time.
- the extra space required for the electronically actuated micro-valves is minimal and adds little bulk or expense and can be assembled using commercially available devices. Additional possibilities involving the use of fewer than 4 valves are described below.
- An economical pump system suitable for use in the methods of the invention is a micro-pump known as MEMS (Micro-Electro-Mechanical System), being developed for diabetes by Debiotech under the brand name Chronojet.
- MEMS Micro-Electro-Mechanical System
- the use of two such micro- pumps in a unitary device adds little bulk and only minimal expense to existing designs.
- the two delivery lines can be merged (in the sense that the two drugs come into direct contact) at the point at which they connect to the cannula or similar micro-needle device used to puncture the skin and deliver the drug.
- a single split-lumen (dual lumen) line is used instead of two physically separate lines. This method has the advantage that the patient has only to route one flexible delivery line rather than two.
- two standard lines physically adhered along their lengths can be used in accordance with the methods ofthe invention to achieve the same advantage.
- the pump of the invention is a currently used insulin pump modified to have two drug reservoirs instead of one, each being independently administered by a single (or dual) pump and a single control system to manage the quantity and relative timing of administration of the two drugs.
- the device can in some embodiments comprise 1, 2 or 4 valves and appropriate connective tubing. Schematics of devices that can be used in accordance with the methods ofthe present invention are shown in Figure 3, 4, and 5.
- the insulin reservoir (1) and the glucagon reservoir (2) have lines in fluid communication with pump (3) and then on to the cannula (5) via split lumen delivery line (4) by way of 4 valves (6) and (7).
- valves (6) When valves (6) are open and valves (7) are closed, only insulin is pumped. When valves (6) are closed and valves (7) are open, only glucagon is pumped. In this way, a single pump may be used to deliver insulin or glucagon to the patient, either simultaneously or separately, with minimal mixing of the two substances by virtue of delivery through a split lumen delivery line in which the liquids only mix at the cannula, i.e. the point of deliver.
- the insulin reservoir (1) and the glucagon reservoir (2) have lines in fluid communication with pump (3) and then on to the cannula (5) via split lumen delivery line (4) by way of 2 valves (6) and (7).
- the glucagon delivery is automatically administered over the appropriate period (for example continuously between the 3rd and 5th hours following the manual instruction to deliver the prandial insulin).
- the control logic required to produce such a sequence of events can be programmed into the pump.
- FIG. 1 A typical hypothetical patient is an adult male, 35 years of age, weighing 75 kg, having type-1 diabetes since the age of 15 and using insulin therapy from the time of diagnosis. He has been on a number of different insulin regimens previously with less than optimal glycemic control. In the last 5 years, he has begun to develop significant background retinopathy, mild renal insufficiency, and hypertension, and is concerned that these complications will continue to progress rapidly unless he is able to improve glycemic control from his current glycosylated hemoglobin level of 7.8%.
- the dose of ULTRALENTE has been adjusted to provide basal replacement of insulin, while the dose of prandial LISPRO varies depending upon the prevailing pre-injection serum glucose and total calories and carbohydrate content of each meal.
- the pump provides a continuous feed to simulate basal insulin over the long term.
- the patient uses ASPART (NOVOLOG) as his insulin of choice.
- the pump, reservoir, and control mechanism in this illustrative case, the MEDTRONIC MTNIMED PARADIGM INSULIN PUMP
- the pump, reservoir, and control mechanism can be attached at various sites about the body ofthe patient (most commonly on the belt, for example), and is linked by a flexible plastic tube to the micro-cannula he has inserted in his abdomen, thigh, or arm (women tend to place the infusion site in the lower abdomen while men usually choose the upper abdomen).
- the patient has programmed the device to deliver 1 IU of insulin every 50 minutes (20 units a day).
- the device programs the device to release an amount of insulin (between 3 and 8 units) appropriate to his meal situation (pre-meal glucose, total calories, and carbohydrate content). He does this by pushing the appropriate buttons on the device (or by use of a remote control device, if available) to select the size ofthe insulin bolus required.
- the device is independently cannulized and independently controlled for continuous subcutaneous infusion of glucagon when desired.
- the patient is instructed to practice the invention as follows. After taking a meal, the patient administers his prandial insulin (3-8 units) and at the same time programs his glucagon pump to administer 1/50th of a unit (20 ⁇ g) of glucagon over three hours and timed to begin 2-3 hours after administration of his prandial insulin.
- the continuous release of glucagon produces a smoother profile with less of a peaked appearance and decay period than with a single subcutaneous injection of glucagon.
- glucagon The increased availability of glucagon during this patient's period of greatest susceptibility to hypoglycemia substantially decreases both the likelihood and severity of such events.
- the dosage of infused insulin can be increased to maintain euglycemia during the period of glucagon administration.
- the patient is provided with sufficient glucagon to serve as a cushion or buffer to the unopposed action of insulin so as to prevent the risk of a hypoglycemic episode.
- the administration of glucagon enables the patient to maintain good glycemic control without the excessive risk of frequent and severe hypoglycemia.
- the invention may be practiced by administering glucagon by pump and administering insulin parenterally, including by pump or other subcutaneous administration.
- Pumps suitable for insulin administration are also suitable for glucagon administration and are discussed in Example 2.
- Insulin can be administered parenterally as described in Example LA.i. Instead of injecting glucagon as described in Example l.A.i, however, the pump is programmed (or actuated) to deliver glucagon continuously between hours 2 and 5 after the meal.
- the total dose of glucagon released is approximately 3/200ths of a unit over those three hours, this being sufficient to provide protection from hypoglycemia.
- Insulin Administered Transdermally [Including Patch and Topical Cream]
- Insulin may be administered transdermally in the practice ofthe invention.
- the patient administers his insulin needs by use of transdermal patch (or cream).
- the patient uses an insulin pump (containing not insulin but glucagon) to administer glucagon to prevent hypoglycemia in the early morning.
- the patient programs his pump to deliver l/200th of a unit of glucagon between the hours of 01 :00 and 02:00, the period during which he is most susceptible to hypoglycemia.
- the patient is able to maintain euglycemia using the methods of the present invention without the risk of hypoglycemia occurring during his sleep.
- Example 4 describes the administration of insulin by inhalation. It will be understood by those skilled in the art that similar methods can be employed when insulin is administered buccaly, nasally or sublingually. The patient will either continue to administer his basal need via GLARGINE (LANTUS), or he will utilize an insulin inhaler to administer basal insulin needs. The patient will administer his prandial insulin need (equivalent to between 5 and 10 units administered by subcutaneous admimstration) using his insulin inhaler (either pulmonary, nasally, buccaly or sublingually).
- GLARGINE LANTUS
- the patient will administer his prandial insulin need (equivalent to between 5 and 10 units administered by subcutaneous admimstration) using his insulin inhaler (either pulmonary, nasally, buccaly or sublingually).
- an insulin pump (containing glucagon rather than insulin) is programmed (or actuated) to deliver glucagon continuously between hours 2 and 5 after the meal.
- the total dose of glucagon released is approximately 3/200ths of a unit over those three hours, this being sufficient to provide the patient with protection from hypoglycemia during his period of greatest susceptibility.
- transdermal patches for the delivery of therapeutic drugs is increasingly more common. Patches provide a non-invasive and easy method of delivering some drugs to the bloodstream. Nicotine and hormone replacement therapies are perhaps the best known uses of this technology.
- One of the characteristics of drug delivery by transdermal patch is that the rate of delivery is typically constant and persists for a long period of time (as long as the patch is worn). This characteristic has proven beneficial in the area of pain management (FENTANYL) and nicotine replacement therapy, in which long duration flat profiles are ideal. This characteristic makes the transdermal patch suitable for basal replacement of insulin or glucagon. See PCT patent publication No. WO0243566, incorporated herein by reference.
- Figure 6 illustrates the effect of molecular weight and lipophilicity on the rate of transdermal transport in case of permeation (upper and lower grey curve for the more or less lipophilic substances, respectively) or of the TRANSFEROME® mediated penetration (black line and bullets). Grey bullets represent the commercial drugs in transdermal patches. Regardless ofthe technology, the ability to efficiently transport peptides transdermally is proven and imminent. In particular, both insulin and glucagon can be delivered transdermally, thus enabling the invention to be practiced using transdermal patches and similar devices.
- a variety of possible patch structures and matrices are envisaged according to the specific mode of use intended.
- Glucagon patches can be formulated to provide post-prandial glucagon for protection from hypoglycemia or basal glucagon replacement.
- the invention can be practiced using patch matrices comprising combinations of these basic types, either together in the same matrix or separately in sub-matrices.
- Topical creams may be used as an alternative to use of a patch.
- prandial insulin matrices For prandial insulin matrices, short acting insulins such as LISPRO (HUMALOG) or ASPART (NOVOLOG) can be used.
- the prandial insulin matrix is typically applied at or at some time before mealtimes, according to its rapidity of onset.
- a prandial insulin patch which minimizes the time to onset can be used so that the patch is applied near to mealtimes.
- the time to onset depends on the insulin concentration and the nature of the formulation. For example, a simple wet-matrix of insulin has slower onset than an insulin patch formulated according to U.S. Patent No. 5,707,641. Monomeric insulin will act faster and be more easily absorbed than larger clusters of insulin molecules, because molecular size impacts bioavailability from transdermal patches.
- a number of different methods of managing the delivery of prandial insulin can be utilized in practice of the present invention.
- patches of different concentrations can be used for fixed periods of time, and the concentration selected by the patient would depend on the amount of carbohydrate eaten.
- the duration for which the patch is worn could be fixed.
- the patch would not necessarily be exhausted on removal, i.e. it could deliver a fixed concentration throughout its use.
- single concentration prandial patches could be employed as follows. The time the patch is worn is varied according to the amount of carbohydrate eaten. The patch would not necessarily be exhausted on removal, i.e. it could deliver a fixed concentration throughout its use.
- prandial patches containing fixed doses of insulin could be used.
- the advantage of a self-exhausting patch is that failure to remove them does not of itself carry the risk of hypoglycemia. Such a patch would be substantially exhausted on removal and the rate of infusion would be front loaded.
- the prandial insulin patch used has a variable insulin concentration (appropriate to the amount of carbohydrate consumed), has a very rapid onset (preferably immediate but not more than one hour), is removed or deactivated after a fixed length of time (preferably from between 3 and 5 hours) and activated at (or no longer than one hour before) mealtimes.
- Prandial glucagon patches are applied at mealtimes or at some predetermined time after the meal according to the rapidity of onset associated with the patch.
- the rate of onset is determined both by the concentration of the glucagon used and the nature of the formulation used. For example, a simple wet-matrix of glucagon would be expected to have a slower onset than a glucagon patch formulated according to the techniques described in U.S. Patent No. 5,707,641.
- the glucagon patch is designed so that peak output of glucagon is reached at some time between 2 and 5 hours after application. This patch is applied at mealtimes.
- prandial insulin and prandial glucagon are administered by transdermal patch.
- This can be achieved in a variety of ways, including: (i) use of a single matrix of glucagon and insulin admixed; (ii) use of a single compartment with two sub matrices, one containing insulin and the other containing glucagon; (iii) use of a single patch containing two compartments, one containing insulin and the other containing glucagon, both compartments being activated and deactivated simultaneously; and (iv) use of two separate patches (or two compartments in a unitary patch), one containing insulin and the other contaimng glucagon, each patch or compartment being independently activated and deactivated.
- Basal insulin is delivered parenterally as described in Example l.A.i by subcutaneous injection of a long-acting insulin such as GLARGINE or ULTRALENTE.
- a long-acting insulin such as GLARGINE or ULTRALENTE.
- method (i) is used (see Example 7). If different matrices are used to achieve the desired pharmacokinetics, then method (ii) or (iii) can be used. If the timing of insulin onset and glucagon onset is not matched, then method (iv) can be used.
- method (ii) above is used.
- the user activates the prandial patch at mealtimes (or preferably within one hour before mealtimes), thereby activating both sub-matrices at the same time.
- a fixed concentration patch is used, the user removes the patch after a period of time proportionate to the amount of carbohydrate ingested.
- a variable concentration patch is used, then the user removes the patch after a fixed period of time, typically between 1 and 3 hours after eating. In one embodiment, fixed concentrations are used. In such an embodiment, the amount of glucagon administered can be increased with the amount of insulin administered.
- both the insulin and glucagon are administered transdermally.
- Two different types of patch can be employed.
- One patch (or compartment) contains a matrix designed to replace basal insulin over a 24 hour period.
- the other patch (or independently controlled compartment) functions in the manner described in Example 3.A.i.
- a single patch (or compartment) containing both the prandial insulin and glucagon in separate sub-matrices with onset times appropriate to applying the prandial patch (or activating the prandial compartment) at (or near) mealtimes is used.
- a unitary device containing four independently actuable compartments is used, one containing basal insulin, which is activated on application and left active for 24 hours, and the other 3 compartments containing the prandial insulin and glucagon in separate sub-matrices within the same compartment, each compartment being separately activated at mealtimes and deactivated at some time after the meal, the time of activation being proportional to the amount of carbohydrate consumed.
- the patient activates one of these prandial compartments [e.g. by pulling away a hermetic plastic seal between the patch and the skin], a process which initiates the transdermal infusion ofthe insulin and glucagon.
- the prandial compartment is deactivated [e.g. by replacing the barrier used to activate the compartment or the total removal of that compartment from the end ofthe patch].
- the insulin formulation in the insulin sub-matrix is short acting insulin, and the patch is designed for rapid onset.
- the glucagon formulation in glucagon sub-matrix is designed to reach efficacious concentrations in the bloodstream between 1 and 3 hours after activation ofthe compartment, hence providing protection from hypoglycemia at the appropriate part of the cycle as described in Example 3.A.i.
- a unitary device which allows for more than 3 meals a day may easily be devised by allowing for more than 3 prandial compartments.
- the prandial drugs may be contained in totally separate (and independently actuated) prandial patches.
- the prandial patch may consist of separate insulin and glucagon compartments so that each may be independently activated and deactivated.
- a unitary device containing separate and independently controlled compartments for insulin and glucagon could have 7 separate compartments, one for basal insulin, 3 for prandial insulin, and 3 for prandial glucagon. The basal patch is designed to replace basal insulin (worn for 24 hours before being replaced).
- the insulin used may be any insulin suitable for transdermal delivery.
- the basal insulin compartment may also optionally contain an amount of glucagon (admixed or in a sub-matrix) sufficient to supply basal glucagon over each 24 hour period. This would have the beneficial effect of providing protection from hypoglycemia throughout the day and in particular during sleep.
- insulin is delivered by inhalation as described in Example 4. This can involve inhalation only for the prandial insulin delivery (basal being delivered parenterally), or all insulin can be delivered by inhalation.
- the patient administers an amount of insulin appropriate to his meal by inhalation (in one or more actuations). He can optionally increase his insulin after a meal as appropriate.
- the glucagon is administered by patch as described in Example 3.A.i.
- the patch (or set of glucagon compartments in a unitary patch) is attached to the skin, and the patch or (sub compartment) is activated at mealtimes.
- the patch is designed to have slow onset, so that the glucagon is only present in the body in efficacious quantity after 2 hours.
- the patch is worn for 4 hours before being removed, the residual glucagon in the body being sufficient to provide protection from hypoglycemia over the required period of 2-5 hours.
- the glucagon in the patch is a long acting glucagon (e.g. iodinated glucagon).
- the patch may then be worn for a shorter time while still ensuring that the protection afforded by the modified glucagon is provided over the required period of 2-5 hours.
- the user can apply the glucagon by means of a transdermal cream, which acts similarly to a transdermal patch.
- the formulation of such a cream can differ from the formulation used in a patch but perform essentially the same function.
- glucagon is administered in this way, it may be advantageous to encapsulate the glucagon in liposomes or TRANSFEROMEs® to prevent the supply of glucagon drying on the skin and reducing bioavailability.
- Example l.A.i the patient's insulin needs are met by parenteral administration.
- the glucagon is administered by patch as described in Example 3.A.i.
- the patch (or set of glucagon compartments in a unitary patch) is attached to the skin and the patch or (sub compartment) is activated at mealtimes.
- the patch is designed to have slow onset, so that the glucagon is only present in the body in efficacious quantity after 2 hours.
- the patch is worn for 4 hours before being removed, the residual glucagon in the body being sufficient to provide protection from hypoglycemia over the required period of 2-5 hours.
- the glucagon in the patch is a long acting glucagon (e.g. iodinated glucagon).
- the patch may then be worn for a shorter time while still ensuring that the protection afforded by the modified glucagon is provided over the required period of 2-5 hours.
- the user may apply the glucagon by means of a transdermal cream, which acts similarly to a transdermal patch.
- the formulation of such a cream can differ from the formulation used in a patch but performs essentially the same function.
- glucagon is administered in this way, it may be advantageous to encapsulate the glucagon in liposomes or TRANSFEROMEs® to prevent the glucagon from drying on the skin and reducing bioavailability.
- the patient's insulin needs are administered by pump as described in Example 2.
- the glucagon is administered by patch as described in Example 3.A.L
- the patch (or set of glucagon compartments in a unitary patch) is attached to the skin and the patch or (sub compartment) is activated at mealtimes.
- the patch is designed to have slow onset, so that the glucagon is only present in the body in efficacious quantity after 2 hours.
- the patch is worn for 4 hours before being removed, the residual glucagon in the body being sufficient to provide protection from hypoglycemia over the required period of 2-5 hours.
- the glucagon in the patch is a long acting glucagon (e.g. iodinated glucagon).
- the patch may then be worn for a shorter time while still ensuring that the protection afforded by the modified glucagon is provided over the required period of 2-5 hours.
- the user may apply the glucagon by means of a transdermal cream, which acts similarly to a transdermal patch.
- the formulation of such a cream may differ from the formulation used in a patch but performs essentially the same function.
- glucagon is administered in this way, it may be advantageous to encapsulate the glucagon in liposomes or TRANSFEROMEs® to prevent the glucagon from drying on the skin and reducing bioavailability.
- Bioavailability depends primarily on the aerosol particle size (most existing systems only deliver 10%-20% ofthe drug administered to the alveoli) rather than on the nature ofthe drug being administered. When the drug being delivered actually reaches the alveoli, its bioavailability is then very high almost regardless of the drug in question. Because the technical problems (and solutions) associated with delivering insulin are similar to those for delivering glucagon, the solutions enabling delivery of insulin are directly applicable to similarly sized macromolecules like glucagon.
- the present invention provides dry powdered formulations prepared by admixing insulin and glucagon. The use of inhalers for delivering insulin is primarily aimed at supplying rapid insulins for prandial purposes. Long acting insulins can be delivered by inhalation if desired.
- the invention can be practiced using inhalers in a number of ways, including with insulin and glucagon in separate inhalers; with insulin and glucagon admixed in a fixed ratio in an inhaler; with a dual chamber inhaler in which insulin and glucagon are administered separately; and with dual chamber inhalers in which insulin and glucagon are administered simultaneously.
- prandial inhalers typically contain rapid acting insulins, they are unsuitable (in the way that insulin pumps are) for the delivery of basal insulin.
- a separate pump or chamber is provided in accordance with the invention if both prandial and basal insulins are to be delivered by inhalation.
- Insulin Administered by Inhalation includes Pulmonary. Buccal. Nasal and
- the hypothetical patient administers basal insulin using ULTRALENTE by subcutaneous injections at a dosage level of 20 units administered at bedtime.
- he may choose to administer the same drug (in a dose that would provide a daily bioavailability of 20 units) by inhalation.
- It may also be beneficial or desirable for him to administer the basal dose by inhaler at a number of times during the day, for example, at mealtimes in addition to bedtime. Because there is a slight delay (approximately 20 minutes) before insulin attains significant serum concentration when compared to subcutaneous delivery, the user will administer his prandial insulin requirement approximately 20 minutes before eating. He does this by administering between 25 and 50 units (assuming a bioavailability of approximately 20%) of insulin by means of a metered dose inhaler.
- the inhaler may be dose alterable (see U.S. Patent Nos. 5,970,973; 5,672,581 ; 5,660,166; 5,404,871; and 5,450,336) or similar to currently used asthmatic devices, which deliver fixed and preset doses on each actuation. Whichever type is used, it may be desirable to administer the insulin in multiple actuations. By so doing, the patient can tailor his intake according to the amount of carbohydrate he actually consumes, rather than the amount he expects to eat, by "topping up" his dose at some time after beginning the meal. Furthermore, the more actuations used to administer the insulin, the better the corresponding dose reliability (reproducibility), because inhalation administration tends to vary from actuation to actuation, and multiple actuation delivery has an averaging or smoothing effect.
- the glucagon inhaler is used to administer a dose equivalent to l/200th of a unit of glucagon per hour parenterally between hours 2 and 5 following the meal.
- a different inhaler for each type of insulin and glucagon is used.
- a unitary inhaler with at least 2 drug chambers (for prandial insulin, glucagon and optionally basal insulin) and capable of independent actuation is used.
- Example l.A.i the patient administers his basal and prandial insulin parenterally. Because the risk of hypoglycemia associated with using LISPRO insulin typically occurs between 2 and 5 hours after eating, the glucagon inhaler is used to administer a dose equivalent to l/200th of a unit of glucagon per hour parenterally between hours 2 and 5 following the meal. Alternatively, a modified glucagon of long-acting duration (e.g. iodinated glucagon) with delayed onset is used in the glucagon inhaler and administered at mealtimes with the prandial insulin.
- a modified glucagon of long-acting duration e.g. iodinated glucagon
- Example 2.A basal and prandial insulin are delivered by pump.
- the risk of hypoglycemia arises after 2 to 3 hours, and so the patient administers glucagon by inhaler 2 hours after eating. He administers one puff from a metered dose inhaler at hours 2, 3 and 4, thus providing protection during the period of susceptibility.
- the dose per actuation corresponds to 1 /200th of a unit of glucagon administered parenterally.
- a modified glucagon of long-acting duration e.g. iodinated glucagon
- iodinated glucagon with delayed onset is used in the glucagon inhaler and administered at mealtimes with the prandial insulin.
- Example 3.A.ii the patient administers his insulin (both basal and prandial) by transdermal patch or by topical cream.
- the risk of hypoglycemia arises after 2 to 3 hours, and so the patient administers glucagon by inhaler 2 hours after eating. He administers one puff from a metered dose inhaler at hours 2, 3 and 4, thus providing protection during the period of susceptibility.
- the dose per actuation corresponds to 1 /200th of a unit of glucagon administered parenterally.
- a modified glucagon of long-acting duration e.g. iodinated glucagon
- a modified glucagon of long-acting duration e.g. iodinated glucagon
- Example 1 the insulin and glucagon were administered parenterally and separately.
- the two drugs are administered simultaneously an admixed form.
- Insulin and glucagon may be admixed with little if any interaction or degradation of either product.
- non-diabetics it is typically found that following the increased insulin output after a meal of carbohydrate there is an associated increase in glucagon output (actually a restoration of output following the initial depression of glucagon output due to the initial gut-induced rise in blood sugar after the ingestion of carbohydrate). This pattern of insulin production followed by glucagon production assumes a relatively fixed relationship.
- glucagon provides protection over the period required
- One formulation of glucagon provided by the invention has both a delayed release and an extended release [e.g. delayed by 2 to 3 hours and releasing over approximately 3 hours].
- Iodinated glucagon has extended activity (measured in terms of elevated glucose levels) of between 1 and 3 hours, depending on the extent of iodination.
- LISPRO insulin and BGlucagon are admixed so that the modified glucagon is present at approximately 1.5% by weight ofthe insulin in the mixture (keeping the concentration of insulin per ml in our LISPRO formulation constant). Because of the longer lasting effect of the modified glucagon, a smaller proportion of glucagon to insulin by weight will be required.
- the hypothetical patient then administers between 5 and 10 units (measured in terms of the insulin contained therein) of the insulin-glucagon formulation at mealtimes in the standard way. In so doing, he administers between 3/800ths and 3/400ths of a unit of modified glucagon. Given the longer action of the modified glucagon, this provides (assuming the modified glucagon has for example twice the effect on glucose levels compared to standard glucagon) the same protection as described in Example l.A. The glucagon so administered will be efficacious continuously between hours 2 and 5 as required.
- Example 6 Co-administration of Glucagon and Insulin.
- the method of the invention may also be practiced using pump-based administration of an admixture of both insulin and glucagon.
- This method provides protection from hypoglycemia in direct proportion to the amount insulin used and with a built in delay. It also replaces basal levels of glucagon throughout the day and especially after meals, as it will also be administered with the basal insulin administered by the pump.
- the invention can be practiced using standard pumps currently available and described in Example 2.
- the insulin cartridges used will contain a mixture of insulin and glucagon (optionally modified release glucagon), with the glucagon component being between 0.1 and 5 % (preferably between 0.5 and 3%), and typically 1.5% by weight compared to the insulin component.
- the insulin/glucagon mixture is then administered by pump (for both basal and prandial insulin).
- the resulting glucagon (modified glucagon) plasma concentrations will map onto the insulin profile but with the attenuating characteristics of the glucagon variant used. This is illustrated in Figure 7. This method will provide protection from hypoglycemia over the period of susceptibility as required.
- the pump is equipped with a glucose sensor (see U.S. Patent No. 5,474,552).
- Example 7 Co-administration of Glucagon and Insulin. Admixed. Transdermally for the Control of
- both the insulin and glucagon are administered by transdermal delivery.
- the prandial insulin and glucagon are admixed in the same matrix or cream.
- Two different types of patch can be employed.
- One patch (or compartment) will contain a matrix designed to replace basal insulin over a 24 hour period.
- the other patch (or independently controlled compartment) functions in the manner described in Example 3.A.i and provides prandial glucagon and insulin in a single matrix.
- glucagon and insulin are matched so that when the patch is actuated, insulin reaches efficacious plasma levels very quickly whereas the glucagon only reaches efficacious levels after 2-3 hours.
- the patch is applied at mealtimes and preferably no more than one hour before the meal.
- a unitary device containing four independently actuable compartments is used, one containing basal insulin, which is activated on application and left active for 24 hours, and the other 3 compartments containing the prandial insulin and glucagon in the same matrix, each compartment being separately activated at (or near) mealtimes and deactivated at some time after the meal, the time of activation being proportional to the amount of carbohydrate consumed.
- the patient activates one of these prandial compartments [e.g. by pulling away a hermetic plastic seal between the patch and the skin], a process which initiates the transdermal infusion of the admixed insulin and glucagon.
- the prandial compartment is deactivated [e.g. by replacing the barrier used to activate the compartment or the total removal of that compartment from the end ofthe patch].
- the combined insulin and glucagon formulation in the prandial compartment contains short acting insulin, and the patch is designed for rapid onset ofthe insulin.
- the glucagon component is designed to reach efficacious concentrations in the bloodstream between 1 and 3 hours after activation of the compartment, hence providing protection from hypoglycemia at the appropriate part ofthe cycle as described in Example 3.A.i.
- a unitary device which allows for more than 3 meals a day can be used and contains more than 3 prandial compartments.
- the basal patch is designed to replace basal insulin (worn for 24 hours before being replaced).
- the insulin used may be any insulin suitable for transdermal delivery. It may be advantageous to use intermediate duration insulin in preference to short-acting insulin so that any variation in insulin absorption over the lifetime of the patch would be minimized by the relatively long lifetimes ofthe insulin involved.
- the basal insulin compartment may also optionally contain an amount of glucagon (admixed) sufficient to supply basal glucagon over each 24 hour period. This would have the beneficial effect of providing protection from hypoglycemia throughout the day and in particular during sleep.
- the present invention provides methods and pharmaceutical formulations for delivery of glucagon admixed with insulin by inhalation.
- a long acting glucagon such as, for example, iodinated glucagon as described in US Patent No. 3,897,551, e.g. 12 G
- LISPRO insulin is admixed with LISPRO insulin and delivered by a typical insulin inhaler (e.g. as disclosed in patent US Patent No. 5,970,973).
- Basal insulin may be delivered in the standard way by subcutaneous injection, as described in Example 1 A, or it may be delivered by inhaler.
- Glucagon may optionally be included in this formulation in an extended release formulation if desired to provide basal glucagon replacement.
- the insulin powder used is admixed with the modified glucagon so that the modified glucagon content is between 0.1% and 5% (preferably between 0.5% and 3%), and typically 1.5% by weight compared to the insulin.
- the modified glucagon bioavailability is estimated to be the same as that of the insulin used. If the particular formulation used results in a different bioavailability, the glucagon fraction will be increased or decreased accordingly.
- the patient will administer the combined insulin and glucagon at mealtimes to provide systemic insulin equivalent to between 5 and 10 units. Assuming bioavailability of approximately 20%, this involves administering between 25 and 50 units of insulin and between about 3/400th and 3/800th of a unit of modified glucagon.
- modified glucagon with a long half life may be used to ensure that glucagon levels are elevated over an extended period. Administered in this way, the glucagon will be correctly and appropriately timed to provide protection from hypoglycemia.
- the patient administers his insulin using any of the methods described herein and administers a glucagon pill as required, for example, with each of his meals, to prevent hypoglycemia.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ541365A NZ541365A (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
CA002509755A CA2509755A1 (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
AU2003303634A AU2003303634B2 (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
MXPA05006994A MXPA05006994A (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia. |
EP03814932A EP1578437A4 (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US10/540,803 US7314859B2 (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
JP2005508608A JP2006514990A (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for prevention and control of insulin-induced hypoglycemia |
US11/169,825 US7655618B2 (en) | 2002-12-27 | 2005-06-28 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
NO20053537A NO20053537L (en) | 2002-12-27 | 2005-07-19 | Preparations and methods for the prevention and control of insulin-induced hypoglycemia. |
US11/927,621 US7678763B2 (en) | 2002-12-27 | 2007-10-29 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US11/927,535 US7678762B2 (en) | 2002-12-27 | 2007-10-29 | Methods for reducing the risk of hypoglycemia |
US11/927,587 US20080160072A1 (en) | 2002-12-27 | 2007-10-29 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US11/927,513 US7683027B2 (en) | 2002-12-27 | 2007-10-29 | Methods relating to hypoglycemic unawareness |
US11/963,584 US7642232B2 (en) | 2002-12-27 | 2007-12-21 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43673502P | 2002-12-27 | 2002-12-27 | |
US60/436,735 | 2002-12-27 | ||
US45497203P | 2003-03-14 | 2003-03-14 | |
US60/454,972 | 2003-03-14 | ||
US47034603P | 2003-05-13 | 2003-05-13 | |
US60/470,346 | 2003-05-13 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10540803 A-371-Of-International | 2003-12-23 | ||
US11/169,825 Continuation-In-Part US7655618B2 (en) | 2002-12-27 | 2005-06-28 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US11/963,584 Continuation US7642232B2 (en) | 2002-12-27 | 2007-12-21 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004060387A1 true WO2004060387A1 (en) | 2004-07-22 |
Family
ID=32719167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041103 WO2004060387A1 (en) | 2002-12-27 | 2003-12-23 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
Country Status (11)
Country | Link |
---|---|
US (2) | US7314859B2 (en) |
EP (1) | EP1578437A4 (en) |
JP (1) | JP2006514990A (en) |
KR (1) | KR20050086948A (en) |
CN (1) | CN1732012A (en) |
AU (1) | AU2003303634B2 (en) |
CA (1) | CA2509755A1 (en) |
MX (1) | MXPA05006994A (en) |
NO (1) | NO20053537L (en) |
NZ (1) | NZ541365A (en) |
WO (1) | WO2004060387A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1778266A2 (en) * | 2004-06-29 | 2007-05-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US9457142B2 (en) | 2009-12-01 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Device and method for delivery of two or more drug agents |
CN110446496A (en) * | 2017-02-03 | 2019-11-12 | 范德比尔特大学 | For treating system, composition and the method for diabetes |
US20220064248A1 (en) * | 2018-12-21 | 2022-03-03 | HANMl PHARM. CO., LTD | Pharmaceutical composition including insulin and glucagon |
US11471592B2 (en) | 2009-09-02 | 2022-10-18 | Becton, Dickinson And Company | Extended use medical device |
RU2823246C2 (en) * | 2018-12-21 | 2024-07-22 | Ханми Фарм. Ко., Лтд. | Pharmaceutical composition containing insulin and glucagon |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
PT1196430E (en) | 1999-06-29 | 2012-04-18 | Mannkind Corp | Purification and stabilization of peptide and protein pharmaceutical agents |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
AU2004296821B2 (en) * | 2003-12-05 | 2011-05-12 | Carefusion 303, Inc. | Patient-controlled analgesia with patient monitoring system |
DE602005024413D1 (en) | 2004-08-20 | 2010-12-09 | Mannkind Corp | CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS |
ES2540886T3 (en) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Dicetopiperazine salts for drug administration |
US8975227B2 (en) * | 2005-07-15 | 2015-03-10 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
KR101557502B1 (en) | 2005-09-14 | 2015-10-06 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of active agents for crystalline micropaticle surfaces |
ES2572952T3 (en) * | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Glucagon analogs showing physiological solubility and stability |
AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
KR20130123470A (en) * | 2007-10-24 | 2013-11-12 | 맨카인드 코포레이션 | Delivery of active agents |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
WO2009146119A2 (en) | 2008-04-04 | 2009-12-03 | Hygieia, Inc. | System for optimizing a patient's insulin dosage regimen |
US10624577B2 (en) | 2008-04-04 | 2020-04-21 | Hygieia, Inc. | Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus |
US9220456B2 (en) | 2008-04-04 | 2015-12-29 | Hygieia, Inc. | Systems, methods and devices for achieving glycemic balance |
PL2293833T3 (en) | 2008-06-13 | 2016-08-31 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
TWI532497B (en) * | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
US8992464B2 (en) | 2008-11-11 | 2015-03-31 | Hygieia, Inc. | Apparatus and system for diabetes management |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2401587A2 (en) | 2009-02-27 | 2012-01-04 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US9250106B2 (en) | 2009-02-27 | 2016-02-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
KR20180079458A (en) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
JP6054861B2 (en) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー/エス | New glucagon analogues |
WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
CN103596583B (en) | 2011-03-28 | 2016-07-27 | 诺沃—诺迪斯克有限公司 | Novel glucagon analogs |
EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
RU2483749C2 (en) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Pharmaceutical composition containing insulin and liposomes for topical application in form of biofilm |
RU2483748C2 (en) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Pharmaceutical composition containing insulin and liposomes for topical application in form of plaster |
UA113626C2 (en) * | 2011-06-02 | 2017-02-27 | A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE | |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
JP6352806B2 (en) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー/エス | New glucagon analogues |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
CN105307672B (en) | 2013-04-18 | 2021-01-05 | 诺和诺德股份有限公司 | Stable, extended GLP-1/glucagon receptor co-agonists for medical use |
MX2020009878A (en) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Heat-stable dry powder pharmaceutical compositions and methods. |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
WO2015061693A1 (en) * | 2013-10-24 | 2015-04-30 | Trustees Of Boston University | Infusion system employing an infusion set for preventing mischanneling of multiple medicaments |
WO2015100439A1 (en) | 2013-12-26 | 2015-07-02 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
CN106029088A (en) | 2014-02-18 | 2016-10-12 | 诺和诺德股份有限公司 | Stable glucagon analogues and use for treatment of hypoglycaemia |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
JP2017525656A (en) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | GLP-1 / glucagon receptor co-agonist for medical use |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
AU2015339576B2 (en) | 2014-10-27 | 2020-02-06 | Glytec, Llc | Subcutaneous outpatient management |
AU2016308953B2 (en) | 2015-08-20 | 2020-09-10 | Glytec, Llc | Diabetes management therapy advisor |
CA2995392C (en) * | 2015-09-04 | 2023-08-15 | Hailiang Chen | Stabilized glucagon solutions |
US11013873B2 (en) * | 2017-01-06 | 2021-05-25 | HealthPartners Institite | Methods for treating patients with impaired awareness of hypoglycemia |
JP2024516395A (en) | 2021-04-27 | 2024-04-15 | アードバーク・セラピューティクス・インコーポレイテッド | Combining bitter taste receptor agonists and gut signaling compounds |
GB202109087D0 (en) | 2021-06-24 | 2021-08-11 | Norwegian Univ Sci & Tech Ntnu | Therapeutic methods and devices |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
US6572542B1 (en) * | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB748857A (en) | 1952-12-16 | 1956-05-09 | Nyegaard & Co As | Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity |
GB766994A (en) | 1953-11-13 | 1957-01-30 | Novo Terapeutisk Labortorium A | Improved process in crystallization of insulin |
GB766995A (en) | 1953-11-14 | 1957-01-30 | Novo Terapeutisk Labor As | Improvements in or relating to the production of insulin crystals |
US2902408A (en) * | 1957-09-12 | 1959-09-01 | Organon | Suspensions of drugs destined for injection and process for the preparation thereof |
GB831907A (en) | 1957-09-12 | 1960-04-06 | Organon Labor Ltd | Suspensions of drugs destined for injection and process for the preparation thereof |
GB844434A (en) | 1958-01-31 | 1960-08-10 | Organon Nv | Insulin preparations and process for preparing same |
US3897551A (en) * | 1971-04-05 | 1975-07-29 | Lilly Co Eli | Iodoglucagons and process for prolonging the biological activity of glucagon |
US4003379A (en) * | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US4498843A (en) * | 1982-08-02 | 1985-02-12 | Schneider Philip H | Insulin infusion pump |
IT1170375B (en) * | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Implantable device for measuring body fluid parameters |
CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
DK27885A (en) * | 1985-01-22 | 1986-07-23 | Novo Industri As | PREPARATION OF PEPTIDES |
AT391998B (en) * | 1987-02-02 | 1990-12-27 | Falko Dr Skrabal | Device for determining the concentration of at least one medicinal substance in living organisms |
US4879273A (en) | 1987-05-22 | 1989-11-07 | The Rockefeller University | Glucagon homologs and therapeutic use thereof |
NL8701644A (en) | 1987-07-13 | 1989-02-01 | Cordis Europ | DEVICE FOR DOSING IN THE BODY OF A LIQUID MATERIAL. |
US4839174A (en) * | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US4943435A (en) * | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US5101814A (en) * | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5190041A (en) * | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
JPH04218000A (en) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | Modified polypeptide |
FR2663224B1 (en) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | PARENTERAL GALENIC FORM. |
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
US5527771A (en) * | 1991-01-10 | 1996-06-18 | Amylin Pharmaceuticals, Inc. | Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions |
US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
DK0586589T3 (en) * | 1991-05-24 | 1997-09-22 | Amylin Pharmaceuticals Inc | Amylin or amylin analogue, possibly containing insulin, for the treatment of anorexia and related conditions |
US5814600A (en) * | 1991-05-24 | 1998-09-29 | Amylin Pharmaceuticals Inc. | Method and composition for treatment of insulin requiring mammals |
CH683149A5 (en) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US6114304A (en) * | 1993-09-07 | 2000-09-05 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
US5512468A (en) * | 1993-11-12 | 1996-04-30 | Stratagene | Process of producing highly transformable bacterial cells and cells produced thereby |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
NL9401886A (en) | 1994-05-27 | 1996-01-02 | Dsm Nv | Composition consisting of a dendrimer and an active substance contained in the dendrimer, a method of preparing such a composition and a method of releasing the active substance. |
US5474552A (en) * | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
JP4067058B2 (en) | 1995-03-10 | 2008-03-26 | 中村 敏一 | PEGylated HGF |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
IL114673A (en) | 1995-07-19 | 2000-12-06 | Hadasit Med Res Service | Pharmaceutical compositions containing protein for oral administration |
US5849322A (en) * | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
US5741211A (en) * | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
CN1154726C (en) | 1995-12-27 | 2004-06-23 | 基因技术股份有限公司 | OB protein derivatives having prolonged half-life |
AU2549297A (en) * | 1996-03-28 | 1997-10-17 | Board Of Trustees Of The University Of Illinois, The | Materials and methods for making improved echogenic liposome compositions |
IL118003A0 (en) * | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
JP3149958B2 (en) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | GLP-1 derivative |
ATE342729T1 (en) | 1997-01-15 | 2006-11-15 | Phoenix Pharmacologics Inc | MODIFIED TUMOR NECROSIS FACTOR |
MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
US5869062A (en) * | 1997-05-27 | 1999-02-09 | Oliver; Benjamin | Skin treatment composition |
US5919216A (en) * | 1997-06-16 | 1999-07-06 | Medtronic, Inc. | System and method for enhancement of glucose production by stimulation of pancreatic beta cells |
US6093167A (en) * | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US6573238B2 (en) * | 1997-11-07 | 2003-06-03 | Chiron Corporation | Method for producing sustained-release formulations |
US6437092B1 (en) * | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
US6107489A (en) * | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
KR19990085365A (en) * | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
RU2205188C2 (en) * | 1998-06-30 | 2003-05-27 | Ново Нордиск А/С | Seed crystals for preparing peptides or proteins |
EP1137431A1 (en) * | 1998-12-04 | 2001-10-04 | Provalis UK Limited | Pharmaceutical compositions containing insulin |
US20020114829A1 (en) * | 1998-12-18 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved liposome compositions |
US6360888B1 (en) * | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6261280B1 (en) * | 1999-03-22 | 2001-07-17 | Medtronic, Inc | Method of obtaining a measure of blood glucose |
CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
CA2501421A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
US6461331B1 (en) * | 1999-05-21 | 2002-10-08 | Minimed Inc. | Device and method for infusion of small molecule insulin mimetic materials |
US20020026141A1 (en) * | 1999-11-04 | 2002-02-28 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US6540982B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
JP2003524652A (en) * | 2000-02-29 | 2003-08-19 | ツァン,ツィエ | Improved transdermal drug patch |
US6548049B1 (en) | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6565833B1 (en) | 2000-05-01 | 2003-05-20 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
AU2001289079A1 (en) | 2000-09-13 | 2002-03-26 | Praecis Pharmaceuticals Incorporated | Pharmaceutical compositions for sustained drug delivery |
JP5170931B2 (en) | 2000-10-16 | 2013-03-27 | 中外製薬株式会社 | PEG-modified erythropoietin |
AU2002230509A1 (en) | 2000-11-28 | 2002-06-11 | Martin G. Baum | Devices and methods for treating low blood sugar levels |
UA81897C2 (en) | 2000-12-07 | 2008-02-25 | Эли Лилли Энд Компани | Normal;heading 1;heading 2;GLUCAGON-LIKE PEPTIDE 1 HETEROLOGOUS FUSION PROTEIN FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS |
US6656590B2 (en) * | 2001-01-10 | 2003-12-02 | Cabot Corporation | Coated barium titanate-based particles and process |
WO2002056940A2 (en) * | 2001-01-22 | 2002-07-25 | Integrated Sensing Systems, Inc. | Sensing catheter system and method of fabrication |
AU2003274601A1 (en) * | 2002-11-18 | 2004-06-15 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
WO2004060387A1 (en) | 2002-12-27 | 2004-07-22 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7806854B2 (en) | 2005-05-13 | 2010-10-05 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
-
2003
- 2003-12-23 WO PCT/US2003/041103 patent/WO2004060387A1/en active Application Filing
- 2003-12-23 KR KR1020057012139A patent/KR20050086948A/en not_active Application Discontinuation
- 2003-12-23 MX MXPA05006994A patent/MXPA05006994A/en unknown
- 2003-12-23 CA CA002509755A patent/CA2509755A1/en not_active Abandoned
- 2003-12-23 CN CNA2003801075753A patent/CN1732012A/en active Pending
- 2003-12-23 AU AU2003303634A patent/AU2003303634B2/en not_active Ceased
- 2003-12-23 EP EP03814932A patent/EP1578437A4/en not_active Withdrawn
- 2003-12-23 JP JP2005508608A patent/JP2006514990A/en active Pending
- 2003-12-23 US US10/540,803 patent/US7314859B2/en not_active Expired - Fee Related
- 2003-12-23 NZ NZ541365A patent/NZ541365A/en unknown
-
2005
- 2005-07-19 NO NO20053537A patent/NO20053537L/en not_active Application Discontinuation
-
2007
- 2007-12-21 US US11/963,584 patent/US7642232B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
US6572542B1 (en) * | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
Non-Patent Citations (1)
Title |
---|
See also references of EP1578437A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678762B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Methods for reducing the risk of hypoglycemia |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7683027B2 (en) | 2002-12-27 | 2010-03-23 | Diobex, Inc. | Methods relating to hypoglycemic unawareness |
US7642232B2 (en) | 2002-12-27 | 2010-01-05 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7678763B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
EP1778266A2 (en) * | 2004-06-29 | 2007-05-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
EP1778266A4 (en) * | 2004-06-29 | 2009-09-09 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US11471592B2 (en) | 2009-09-02 | 2022-10-18 | Becton, Dickinson And Company | Extended use medical device |
US9457142B2 (en) | 2009-12-01 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Device and method for delivery of two or more drug agents |
US10350355B2 (en) | 2009-12-01 | 2019-07-16 | Sanofi-Aventis Deutschland Gmbh | Device and method for delivery of two or more drug agents |
US10695491B2 (en) | 2009-12-01 | 2020-06-30 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device including motion detection system |
US10765808B2 (en) | 2009-12-01 | 2020-09-08 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device including motion detection system |
US11524112B2 (en) | 2009-12-01 | 2022-12-13 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device and method of operation |
US11090435B2 (en) | 2009-12-01 | 2021-08-17 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device and electro-mechanical injection device |
CN110446496A (en) * | 2017-02-03 | 2019-11-12 | 范德比尔特大学 | For treating system, composition and the method for diabetes |
EP3576748A4 (en) * | 2017-02-03 | 2020-11-04 | Vanderbilt University | Systems, compositions and methods for treating diabetes |
EP4233876A1 (en) * | 2017-02-03 | 2023-08-30 | Vanderbilt University | Systems, compositions and methods for treating diabetes |
EP3900734A4 (en) * | 2018-12-21 | 2022-10-12 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition containing insulin and glucagon |
US20220064248A1 (en) * | 2018-12-21 | 2022-03-03 | HANMl PHARM. CO., LTD | Pharmaceutical composition including insulin and glucagon |
RU2823246C2 (en) * | 2018-12-21 | 2024-07-22 | Ханми Фарм. Ко., Лтд. | Pharmaceutical composition containing insulin and glucagon |
Also Published As
Publication number | Publication date |
---|---|
US7642232B2 (en) | 2010-01-05 |
KR20050086948A (en) | 2005-08-30 |
EP1578437A1 (en) | 2005-09-28 |
EP1578437A4 (en) | 2006-08-09 |
MXPA05006994A (en) | 2005-10-18 |
US20080096801A1 (en) | 2008-04-24 |
US20060160722A1 (en) | 2006-07-20 |
AU2003303634B2 (en) | 2009-10-01 |
CN1732012A (en) | 2006-02-08 |
US7314859B2 (en) | 2008-01-01 |
CA2509755A1 (en) | 2004-07-22 |
AU2003303634A1 (en) | 2004-07-29 |
JP2006514990A (en) | 2006-05-18 |
NZ541365A (en) | 2009-09-25 |
NO20053537L (en) | 2005-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7314859B2 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
US7655618B2 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
US20230148019A1 (en) | Use of ultrarapid acting insulin | |
JP2006514990A5 (en) | ||
AU2005260025A1 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
ZA200504944B (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
Profit | Exubera®(inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes | |
Patel et al. | Dr. Shweta Bhanot Pandit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2509755 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169196 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/04944 Country of ref document: ZA Ref document number: 200504944 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005508608 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A75753 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057012139 Country of ref document: KR Ref document number: PA/a/2005/006994 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003303634 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003814932 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 541365 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1465/KOLNP/2005 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057012139 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003814932 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006160722 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10540803 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10540803 Country of ref document: US |